Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00248560 · OUTCOME

Response Duration

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer · Source last updated 2019-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
80% Confidence Interval
Time frame
Every 8 weeks

What was measured

Response duration in months

Analysis population: Only those patients that have a recorded CR or PR

Groups in this outcome

Gemcitabine, Docetaxel

Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine. docetaxel: Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine. Gemcitabine: Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Gemcitabine, Docetaxel6

Reported measurements

Source class 1
Values in months · Interval/dispersion: 80% Confidence Interval
GroupValueSpreadLowerUpperComment
Gemcitabine, Docetaxel3.2Not reported2.06.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.0
        upper Limit
        6.1
        value
        3.2
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Response duration in months
dispersion Type
80% Confidence Interval
groups
  1. description
    Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine. docetaxel: Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine. Gemcitabine: Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
    id
    OG000
    title
    Gemcitabine, Docetaxel
param Type
MEDIAN
population Description
Only those patients that have a recorded CR or PR
reporting Status
POSTED
time Frame
Every 8 weeks
title
Response Duration
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice